NCT03953690

Brief Summary

Systemic lupus erythematosus (SLE) is a complex disease whose evaluation in daily practice and clinical research requires consideration of several aspects, in particular disease activity and quality of life. Health systems are increasingly using Patient Reported Outcome measures (PRO) data to measure different dimensions of the disease and its experience. In addition, there is a growing number of "e-health" tools for patients. Indeed, the collection of health-related data via an electronic system makes it possible to modernise and facilitate communication between patients and doctors within the framework of medical follow-up and therapeutic education. Nevertheless, very few studies measure the acceptability and effective long-term use of such tools, particularly in the context of SLE. The Sanoïa patient platform is a digital tool already used in therapeutic areas similar to SLE (discoid lupus erythematosus and rheumatoid arthritis), offering a guarantee of safety and a reduced individual cost. The availability of this health-related quality of life data collection tool via a site and a mobile application adapted to patients with SLE should:

  • Facilitate the collection by patients of their quality of life as part of their routine follow-up (patient access)
  • Limit the impact of patients' clinical profiles on the frequency of the collection of quality of life data
  • Enable internal medicine specialists to systematically use their patients' quality of life data during consultation (physician access). This study therefore proposes to evaluate this digital platform within the framework of SLE by measuring the distribution of access by physicians according to the data reported by patients and according to the characteristics of the facilities where the subjects were recruited for the study. These data will allow us to evaluate the influence of factors extrinsic to patients on the adoption of the tool. This area has been very poorly evaluated in the few studies that have focused on the adoption of such tools.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
221

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 15, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 16, 2019

Completed
10 months until next milestone

Study Start

First participant enrolled

March 19, 2020

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 5, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 5, 2022

Completed
Last Updated

October 2, 2023

Status Verified

September 1, 2023

Enrollment Period

2.7 years

First QC Date

May 15, 2019

Last Update Submit

September 29, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • utilization rate of online patient account

    rate of use of the patient account at least twice, at least 1 month apart, over a 12-month period

    Through study completion, an average of 24 months

Interventions

use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients attending a consultation in their usual treatment centre

You may qualify if:

  • Adult \> 18 years old
  • Having given oral consent for participation
  • Confirmed systemic lupus diagnosis (ACR criteria)
  • Regular follow-up in the centre for more than 12 months
  • With Internet access at home
  • Affiliated with national health insurance system or other system

You may not qualify if:

  • Persons subject to a legal protection measure (curatorship, guardianship)
  • Persons subject to limited judicial protection
  • Adults who are incapable or unable to express their consent
  • Patients who cannot read French
  • Patients whose cognitive status does not allow them to track their health data on a digital platform
  • Patients to be followed up in another centre within 12 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Universitaire

Dijon, 21079, France

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 15, 2019

First Posted

May 16, 2019

Study Start

March 19, 2020

Primary Completion

December 5, 2022

Study Completion

December 5, 2022

Last Updated

October 2, 2023

Record last verified: 2023-09

Locations